Soligenix (SNGX.OB) Completes Enrollment for Phase 1b Clinical Trial of Bioterror Vaccine
Soligenix Inc. is a late-stage biopharmaceutical company focused on developing products to treat potentially fatal side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. The company today reported the completion of enrollment of its phase 1b clinical trial of RiVax™, Soligenix's proprietary recombinant subunit vaccine developed to protect against exposure to ricin toxin. The company said its preliminary results indicate that RiVax appears safe at all doses tested in the company’s panel of volunteers. According to the press release, the phase 1b trial is designed to assess the duration of immune responses using an…